

BMJ Open

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<http://bmjopen.bmj.com>).

If you have any questions on BMJ Open's open peer review process please email info.bmjopen@bmj.com

BMJ Open

Impact on Mental, Physical, And Cognitive functioning of Critical care Time due to COVID-19 (IMPACCT COVID-19): protocol for a multicentre, prospective cohort study

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2021-053610
Article Type:	Protocol
Date Submitted by the Author:	18-May-2021
Complete List of Authors:	Castro-Avila, Ana; University of York, Health Sciences; Universidad del Desarrollo Facultad de Medicina Clínica Alemana, Carrera de Kinesiología Merino-Osorio, Catalina; Universidad del Desarrollo Facultad de Medicina Clínica Alemana, Carrera de Kinesiología González-Seguel, Felipe; Clínica Alemana de Santiago SA, Servicio Medicina Física y Rehabilitación; Universidad del Desarrollo Facultad de Medicina Clínica Alemana, Carrera de Kinesiología Camus-Molina, Agustín; Clínica Alemana de Santiago SA, Servicio Medicina Física y Rehabilitación; Universidad del Desarrollo, Facultad de Medicina Clínica Alemana Universidad del Desarrollo Leppe, Jaime; Universidad del Desarrollo Facultad de Medicina Clínica Alemana, Carrera de Kinesiología
Keywords:	COVID-19, Adult intensive & critical care < INTENSIVE & CRITICAL CARE, REHABILITATION MEDICINE

SCHOLARONE™
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

1
2
3 **Title:** Impact on Mental, Physical, And Cognitive functioning of Critical care Time
4 due to COVID-19 (IMPACCT COVID-19): protocol for a multicentre, prospective
5 cohort study
6
7
8
9

10
11
12 **Abbreviated title:** IMPACCT COVID-19 study protocol
13
14

15
16
17 Ana Castro-Ávila, Catalina Merino-Osorio, Felipe González-Seguel, Agustín
18 Camus-Molina, Jaime Leppe, on behalf of the IMPACCT study group
19
20

21
22
23 Ana Castro-Ávila, PT, MSc, PhD, Department of Health Sciences, University of
24 York, Heslington, United Kingdom. Docente, Carrera de Kinesiología, Facultad de
25 Medicina Clínica Alemana Universidad del Desarrollo, Av. Plaza 680, Las Condes,
26 Santiago, Chile. <https://orcid.org/0000-0003-4475-4325>
27
28
29
30

31
32
33 Catalina Merino-Osorio, PT, MSc, Carrera de Kinesiología, Facultad de Medicina
34 Clínica Alemana Universidad del Desarrollo, Av. Plaza 680, Las Condes, Santiago,
35 Chile. <https://orcid.org/0000-0002-6836-5466>
36
37
38
39

40
41
42 Felipe González-Seguel, PT, MSc, Servicio de Medicina Física y Rehabilitación,
43 Departamento de Medicina Interna, Facultad de Medicina Clínica Alemana
44 Universidad del Desarrollo, Av. Vitacura 5951, Santiago, Chile.
45
46
47
48
49
50
51 <https://orcid.org/0000-0001-9099-2389>
52

53
54 Address all correspondence at: feligonzaezs@udd.cl +(56) 9 89540683.
55
56
57
58
59
60

1
2
3 Agustín Camus-Molina, PT, MSc, Servicio de Medicina Física y Rehabilitación,
4
5 Departamento de Medicina Interna, Facultad de Medicina Clínica Alemana
6
7 Universidad del Desarrollo, Av. Vitacura 5951, Santiago, Chile.
8
9

10 <https://orcid.org/0000-0001-7378-9565>
11
12
13

14 Jaime Leppe, PT, MSc, Carrera de Kinesiología, Facultad de Medicina Clínica
15
16 Alemana Universidad del Desarrollo, Av. Plaza 680, Las Condes, Santiago, Chile.
17
18

19 <https://orcid.org/0000-0002-8663-1182>
20
21
22

23
24 **Number of figures:** 1
25

26 **Reference Mendeley Style:** BMJ Open
27

28 **Word count** (excluding title page, abstract, references, figures, tables and
29
30 strengths and limitations): 3540/4000
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

ABSTRACT (290/300)

Introduction: Intensive care unit (ICU) survivors and their families present a variety of mental, cognitive and physical impairments lasting years. The ongoing pandemic could affect the duration, variety, and severity of these impairments. Our aim is to determine the impact of the COVID-19 pandemic on the physical, mental, and cognitive health of survivors, their families and their treating healthcare professionals in the long-term.

Methods and analysis: Prospective cohort in seven Chilean ICUs with a qualitative component. Sample: 450 adults, able to walk independently, in ICU and mechanical ventilation >48 hours with and without COVID-19. Assessments: Only at ICU discharge, Clinical Frailty Scale, Charlson comorbidity index, mobility (FSS-ICU) and muscle strength (MRC-SS). Cognitive functioning (MOCA-blind), anxiety and depression (HADS), post-traumatic stress (IES-R) symptoms, disability (WHODAS 2.0), quality of life (EQ-5D-3L), employment, and survival will be assessed at ICU discharge, 3 and 6 months. Physical activity (GPAQ and actigraphy) will be measured in a sample at 6 months after ICU discharge. The perceptions of family members regarding the ICU stay and the later recovery will be explored 3 months after discharge. Health care professionals will be invited to discuss the challenges faced during the pandemic using semi-structured interviews.

Ethics and dissemination: The “Impact on Mental, Physical, And Cognitive functioning of Critical care Time due to COVID-19” (IMPACCT COVID-19) study was approved by the local Research and Clinical Trials Unit, the local Ethics Committee (2020-78) and each participating site. All eligible patients will receive

1
2
3 verbal and written information about the study before signing an informed consent
4
5 form. A leaflet containing information about post-intensive care syndrome and
6
7 rehabilitation alternatives will be provided to all participants. Study findings will be
8
9 published in peer-reviewed journals following standard guidelines and
10
11 disseminated through social media and conference meetings.
12
13

14
15
16
17 **Keywords:** COVID-19, critical care, postintensive care syndrome, rehabilitation,
18
19 follow-up studies
20
21
22

23 24 **Strengths and limitations of this study:**

- 25
26 ▪ The mental, physical and cognitive consequences related to the post-
27
28 intensive care syndrome could be greater in periods of high occupancy
29
30 during the pandemic and even more in patients infected with COVID-19.
31
32
- 33
34 ▪ This is the first Chilean multicentre follow-up study assessing functional
35
36 outcomes of mechanically ventilated patients discharged from intensive care
37
38 unit (ICU).
39
- 40
41 ▪ This study will also explore the views and experiences of family members/
42
43 next of kin and health care professionals working during the pandemic.
44
45

46 47 **INTRODUCTION**

48
49 Post-intensive care syndrome (PICS) is a common consequence of an intensive
50
51 care unit (ICU) stay and can last up to 5 years.[1–3] The family members are often
52
53 affected, reporting diminished quality of life and mental health related quality of
54
55 life.[4] About 80% of family members become informal carers and 33% of families
56
57
58
59
60

1
2
3 see a significant reduction of income the first 6 months after discharge.[5] The
4
5 extent to which these problems will be modified by the coronavirus disease 2019
6
7 (COVID-19) pandemic remains unknown.
8

9
10 If under normal circumstances, an ICU stay has detrimental effects, the pandemic
11
12 added two extra factors. Firstly, a rapid and exponential increase in acute care bed
13
14 capacity might have affected the quality of care delivered by spreading too thin
15
16 highly skilled healthcare staff. Secondly, COVID-19 involves a new disease with
17
18 great uncertainties regarding treatment, prognosis and long-term effects. Early
19
20 reports suggest that 64% of patients who were discharged from ICU after severe
21
22 COVID-19 have at least one symptom of PICS at 6 months after discharge[6] and
23
24 32% had anxiety or depression symptoms,[7] which suggests these patients will
25
26 have similar impairments to what has been reported for other ICU survivors
27
28 previously.[8,9] Additionally, infection control protocols meant that healthcare staff
29
30 had to wear personal protective equipment and family visiting was restricted.[10]
31
32 These factors add another layer of potential negative effects due to challenges in
33
34 communication with patients and their family members. Therefore, we hypothesize
35
36 that the prevalence and severity of mental, physical, and cognitive impairments will
37
38 be higher in patients treated in periods of higher bed occupancy and those who
39
40 had severe COVID-19. In the case of family members, we expect that the
41
42 experience of having a next of kin in the ICU during pandemic would be stressful
43
44 and traumatic, but those with social support will cope better. In the case of staff
45
46 members, their experiences will vary greatly depending on their profession and
47
48 workplace, but we expect places with a more open/ less hierarchical structure to
49
50 have coped better with the increase in demand.
51
52
53
54
55
56
57
58
59
60

1
2
3 The primary objective of this study is to compare the trajectory of mental, physical
4 and cognitive impairments at ICU discharge, 3 and 6 months of mechanically
5 ventilated adult patients who survived an ICU stay due to severe COVID-19 or
6 other causes during high and low bed occupancy in the pandemic. Secondary
7 objectives are:
8
9
10
11
12
13

- 14 ● To compare the employment status, quality of life and survival rate at ICU
15 discharge, 3 and 6 months of patients who were admitted to ICU due to
16 severe COVID-19 or other causes during high and low bed occupancy in the
17 pandemic;
18
19
- 20 ● To describe the sedentary behaviour and physical activity levels in a sample
21 of ICU survivors during the COVID-19 pandemic using a one-week
22 actigraphy protocol;
23
24
- 25 ● To explore the psychological and emotional experiences reported by family
26 members/next of kin of patients admitted to the ICU during the COVID-19
27 pandemic;
28
29
- 30 ● To explore the emotional, intellectual, physical and administrative
31 challenges faced by the participating ICU staff during the COVID-19
32 pandemic;
33
34
- 35 ● To evaluate the feasibility of the follow-up from ICU discharge to 3 and 6
36 months during the pandemic.
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

METHODS

Study design and setting

The “Impact on Mental, Physical, And Cognitive functioning of Critical care Time due to COVID-19” (IMPACCT COVID-19) is a prospective, multicentre, cohort study in seven Chilean academic medical-surgical ICUs. This study also involves a qualitative component including semi-structured interviews with family members/next of kin of ICU survivors and with ICU staff from the participating centres. Participating sites are four public and three private hospitals comprising a pooled bed capacity of about 200 ICU beds for both COVID-19 patients and patients admitted for other causes. The IMPACCT COVID-19 study started in October 2020. Data collection is planned until November 2021 to achieve completion of the study in February 2022.

Study population and eligibility criteria

Adult patients (≥ 18 years old) who are mechanically ventilated for at least 48 hours in one of the participating ICUs and do not meet any of the exclusion criteria (**Table 1**) will be invited to participate.

Table 1. Exclusion and stopping follow-up criteria

Exclusion criteria	Rationale
Unable to walk independently 2 weeks prior to ICU admission (with or without a gait aid)	Potential confounding factor
S5q < 5 or CAM-ICU positive within 72 hours after ICU discharge	Unable to evaluate
Patient who do not understand or speak Spanish	Unable to evaluate
Patient unable to communicate verbally	Incomplete assessment data
Burn or severe trauma as admission diagnosis	Incomplete assessment data
Any neurological disorder (i.e. spinal cord injury, stroke and brain tumours) as admission diagnosis	Potential confounding factor
Transferred to a non-participating study centre before ICU discharge assessment	Unable to evaluate
Recent prolonged hospital stay (extended by more than 3 months)	Potential confounding factor
Criteria to stop follow-up	
Re-admission after being ICU discharged	Potential confounding factor
Withdrawal of consent	Incomplete assessment data
Death before 3 or 6 months from ICU discharge	Incomplete assessment data

CAM-ICU, Confusion Assessment Method for the Intensive Care Unit; ICU, intensive care unit; s5q, Standardized Five Questions

Procedure

The planned flow of participants throughout the study is presented in **Figure 1**.

Daily, patients will be screened to identify those who could potentially be discharged from the ICU. Each site coordinator, which is a clinician physiotherapist responsible for the site, will check that the patient is delirium-free (CAM-ICU negative) and cooperative (i.e. using 5 standardised questions: open [close] your eyes; look at me; open your mouth and stick out your tongue; nod your head; raise your eyebrows when I have counted up to five[11]) within 72 hours from ICU discharge. Every patient deemed eligible will be invited to participate and will receive verbal and written information about the study. Patients will be assessed at ICU discharge (T1, defined by the point between medical decision of discharge until 72 hours after), 3 months (T2) and 6 months after ICU discharge (T3). Fifty-eight physiotherapists were trained for the assessments at ICU discharge, which included in-person measurements and self-administered questionnaires. Physiotherapists had to be working in one of the participating ICUs at the time of the training. Training for standardising T1 assessments was delivered by experienced physiotherapists and researchers (ACM, CMO and FGS). For the follow-up assessments (T2 and T3), patients will be contacted via email or telephone to schedule a phone call evaluation performed by trained interviewers.




Figure 1. IMPACCT COVID-19 study flowchart.

COVID-19, coronavirus disease 2019; ICU, intensive care unit.

After the patient agreed to participate and signed the informed consent form, the following baseline data will be collected from the patient clinical records: age, gender, body mass index (BMI), highest educational level achieved (no formal education, primary school, secondary school, undergraduate or postgraduate), admission diagnosis, Charlson Comorbidity Index, duration of mechanical ventilation, length of hospital stay before ICU admission, ICU length of stay, number of intubations and the maximum level of organ system support received.[12]

Measurement Outcomes

The assessment points and measurement instruments are presented in **Table 2**. Measurement instruments were selected according to the recommended Core Outcome Measurement Set for critical illness survivors.[13,14]

Table 2. Schedule of enrolment and follow-up of the IMPACCT COVID-19 study

	Study period		
	Enrolment	Follow-up	
		ICU discharge	3 months from enrolment
Eligibility screening			
Inclusion and exclusion	X		
Invitation to participate			
Informed consent	X		
Patient characteristics			
Age, gender, BMI	X		
Data related to hospitalisation			
Diagnosis, MV days, ICU LOS	X		
Maximum level of organ system support	X		
Pre-admission health and functioning	X		

Charlson Comorbidity Index				
	Educational level	X		
	Employment status	X	X	X
	Clinical Frailty Scale	X	X	X
Physical functioning				
	MRC Sum Score	X		
	FSS-ICU	X		
Cognitive functioning				
	MoCA blind	X	X	X
Mental functioning				
	IES-R	X	X	X
	HADS	X	X	X
Disability and quality of life				
	WHODAS 2.0	X	X	X
	EQ-5D-3L		X	X
Sedentary behaviour and physical activity				
	Actigraphy			X
	GPAQ			X
	Survival rate	X	X	X

BMI, body mass index; EQ-5D-3L, European Quality of Life Health Questionnaire 5 domains; FSS-ICU, Functional Status Score for the Intensive Care Unit; GPAQ, Global Physical Activity Questionnaire; HADS, Hospital Anxiety and Depression Scale; ICU, intensive care unit; IES-R, Impact of Event Scale Revised; IMPACCT COVID-19, Impact on Mental, Physical, And, Cognitive functioning of Critical care Time due to COVID-19; LOS, length of stay; MoCA, Montreal Cognitive Assessment; MRC, Medical Research Council; MV, mechanical ventilation; WHODAS, World Health Organization Disability Assessment Schedule

When available, we used the Chilean version of each instrument, otherwise, the validated version in Spanish. Trained physiotherapists will take an estimated maximum time of 70 minutes to perform the assessment at ICU discharge (T1). A trained interviewer will take an estimated maximum time of 20 minutes to apply the questionnaires by telephone at 3 (T2) and 6 months (T3) after ICU discharge.

The primary outcome measure is disability assessed at 6 months after ICU discharge using the World Health Organization Disability Assessment Schedule 2.0 (WHODAS 2.0) which is recommended for critical illness survivors.[8] The WHODAS 2.0 is a self-reported disability questionnaire based on the International

1
2
3 Classification of Functioning, Disability, and Health (ICF). It includes 36 questions,
4 organised under six domains (cognition, mobility, self-care, getting along, life
5 activities and participation). Each question must be answered based on the
6 perceived difficulty for performing activities using a 5-point scale (none, mild,
7 moderate, severe and extreme).[15] We will use the Spanish version freely
8 available at <https://apps.who.int/iris/handle/10665/170500>. [16] The estimated
9 response time ranges from 5 to 10 minutes when evaluated in-person at ICU
10 discharge and 10 to 20 minutes when evaluated by telephone at 3 and 6 months
11 after ICU discharge.
12
13
14
15
16
17
18
19
20
21
22
23
24
25

26 Secondary outcomes measures

27 *Clinical Frailty Scale*

28
29 The Clinical Frailty Scale (CFS) is a clinical judgment based tool developed for the
30 Canadian Study of Health and Aging to evaluate the degree of frailty in elderly
31 patients.[17] Currently, it is also used for critically ill patients.[18] The CFS
32 evaluates specific domains including physical functioning, activities of daily living
33 (ADL), instrumental ADL, assistance for personal care, comorbidities, and
34 cognition to generate a frailty score using a 9-point scale ranging from 1 (very fit) to
35 9 (terminally ill). A score greater than 4 is considered fragile.[17] We will use the
36 Spanish version and recommended training material by the developers at the
37 Dalhousie University.[17,19] The estimated scoring time ranges from 1 to 5
38 minutes evaluated in-person at ICU discharge considering the status 2 weeks
39 before the onset of symptoms.
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Medical Research Council Sum Score (MRC-SS)

Limb muscle strength will be assessed using the MRC-SS, which consists in a standardised examination of six muscle groups bilaterally (i.e. shoulder abduction, elbow flexion, wrist extension, hip flexion, knee extension and dorsiflexion).[20] All muscle groups are scored using a 6-point scale between 0 and 5 (0 = no visible / palpable contraction; 1 = visible / palpable contraction or no limb movement; 2 = limb movement, but not against gravity; 3 = movement against the gravity over nearly the entire range of motion; 4 = motion against gravity and resistance, subjectively adjusted for gender and age; 5 = normal force). This scale requires an estimated assessment time of 5 to 10 minutes and will be evaluated only at ICU discharge following the method described by Hermans *et al.*[21]

Functional Status Score for the Intensive Care Unit (FSS-ICU)

The FSS-ICU is a mobility instrument to score the level of physical assistance required when performing five functional activities: rolling, transfer from supine to sit, sitting at the edge of the bed, transfer from sitting to stand, and walking.[22] Each activity is scored using a 7-point scale ranging from 0 (not able to perform) to 7 (complete independence). The resulting overall score ranges from 0 to 35 points. Each evaluation requires between 10 and 30 minutes. It will be assessed at ICU discharge using the available and validated Chilean version.[23,24] Due to the limitations during the pandemic, walking will be evaluated inside the room, occasionally forcing the patient to walk with more laps than usual.

Montreal Cognitive Assessment–Blind (MoCA blind)

The MoCA blind is a cognitive screening tool designed to detect cognitive dysfunction in five areas: memory, attention, language, abstraction and orientation. It requires 5 minutes to be completed.[25] Each domain is scored separately for a total score ranging from 0 to 22 points. A score equal to or greater than 18 points is considered normal cognition. To minimize memory bias, the MoCA blind will be assessed using version 7.1 at ICU discharge (in-person), version 7.2 at 3 months (by telephone) and version 7.3 at 6 months (by telephone),[26,27] following the standardised procedure recommended at <https://www.mocatest.org>.

Hospital Anxiety and Depression Scale (HADS)

The HADS is an interviewer or self-administered questionnaire designed to identify anxiety and depressive symptoms in a wide variety of in-hospital patients, which requires between 2 and 5 minutes to be completed.[28] The HADS has fourteen questions, seven for anxiety and seven for depressive symptoms. Each question is rated with a 4-point scale ranging from 0 ("absence") to 3 ("extreme presence"), resulting in a sum score of 21 points per subscale. HADS will be evaluated at ICU discharge and by telephone at 3 and 6 months using the Chilean version.[29]

Impact of Events Scale–Revised (IES-R)

The IES-R is an interviewer or self-administered questionnaire designed to measure the subjective distress caused by traumatic events that has been validated for critical illness survivors.[30] It comprises 22 questions divided in three subscales: intrusion, avoidance, and hyperarousal. Questions are rated in a 5-point

1
2
3 scale ranging from 0 ("not at all") to 4 ("extremely"). The estimated response time
4
5 is 6 minutes. It will be evaluated at ICU discharge and by telephone at 3 and 6
6
7 months using the available Chilean version.[31]
8
9

10 11 12 *European Quality of Life Health Questionnaire (EQ-5D-3L)* 13

14 The EQ-5D-3L is an interviewer or self-administered questionnaire of health status
15 or health-related quality of life, including five domains: mobility, self-care, usual
16
17 activities, pain/discomfort, anxiety/depression and global health state.[32,33] Each
18
19 domain is scored based on 3 levels of severity: no problems, some problems, and
20
21 extreme problems. Additionally, EQ-5D-3L includes a Visual Analog Scale ranging
22
23 from "best imaginable health state" (100) to "worst imaginable health state" (0).
24
25

26 Both parts of the questionnaire take an estimated response time of 2 minutes. It
27
28 will be evaluated by telephone at 3 and 6 months using the Chilean version.[34]
29
30
31
32
33
34

35 *Employment status* 36

37 The employment status will be evaluated at ICU discharge, 3 and 6 months using
38
39 tailored questions regarding current occupation, working hours, and any changes
40
41 to their employment situation as it has been used elsewhere.[35,36]
42
43
44
45

46 *Survival* 47

48 The survival rate will be measured by the percentage of patients still alive at ICU
49
50 discharge, 3 months, and 6 months after ICU discharge. Information on deaths will
51
52 be obtained from death certificates from the Chilean National Civil Registry.
53
54
55
56
57
58
59
60

Sedentary Behaviour and Physical Activity

Sedentary behaviour and physical activity will be measured using a standardized one-week actigraphy protocol according to the Chilean National Health Survey [37,38] using the ActiGraph GT3X (ActiGraph, Pensacola, FL, USA) accelerometer and the Global Physical Activity Questionnaire (GPAQ) in a selected sample of survivors at 6 months after ICU discharge.

Family or next of kin interviews

During the 3-month follow-up call, patients will be asked if a family member or next of kin will be willing to participate in the interview study. Once monthly, we will purposely select a sample of family members to be contacted. The selection will be performed to ensure maximum variation in terms of age, educational level, length of ICU stay, treatment centre and COVID-19 status of the patient that went through ICU. Information about the interview study will be provided over the phone following a script approved by the ethics committee. Once the family members verbally consent, the interview will be scheduled. Interviews will be semi-structured and be recorded for later transcription verbatim. The interviewer is a clinical psychologist with experience conducting interviews and training on providing emotional support for people under distress. We will aim to conduct 18 interviews or more until data saturation is achieved. Interviews will cover four main topic areas: ICU admission, communication during the ICU stay, experience of returning home, and the experience of having a loved one in the ICU. Each transcription will be anonymised, and the recording will be securely deleted.

Critical care staff interviews

Once the bed occupancy in ICU returns to usual levels, recruitment will start. An open call to participate will be made through WhatsApp and Facebook groups of the clinicians working in the participating centres. Additionally, posters will be put in the rest areas to capture a wider population. We will recruit medics, nurses, healthcare assistants and physiotherapists that normally work in an ICU and have patient-facing clinical duties for more than 96 hours during the pandemic. The invitation to participate will lead to a Google form containing information about the study and a short script that constitutes the informed consent. From the list of volunteers, we will purposely sample three professionals per clinical group aiming to maximise variation regarding years of experience and centre where they work. We expect a minimum of 40 interviews, but we will continue recruitment until data saturation is achieved. Interviews will be conducted online or over the phone. Participants will be asked for verbal consent before starting the interview, which will be recorded for later transcription verbatim. Interviews will be semi-structured covering five main topic areas: preparation before the pandemic; intellectual, physical and emotional challenges during the pandemic; and learning for future events.

Follow-up feasibility

The consent rate will be collected, calculating the number of patients who agreed to participate divided by the number of patients who meet selection criteria, expecting a consent rate > 70%. [39] The feasibility over-time during the follow-up will be measured as cohort retention rate, considering the number of patients who

1
2
3 can be contacted and evaluated at 3 and 6 months, expecting a cohort retention
4
5 rate > 70% as elsewhere.[40–42] Additionally, the reasons for the lack of
6
7 assessments will be recorded individually.
8
9

10 11 12 **Sample size calculation** 13

14 All patients meeting the eligibility criteria discharged from ICU between October
15
16 2020 and April 2021 (due to funding constraints) will be invited to participate.
17

18 Based on bed capacity and patient flow from previous years, we estimated that 20
19
20 to 30 mechanically ventilated adult patients are discharged monthly from each
21
22 centre. This means the sampling universe ranges from 840 to 1260 patients.
23
24

25 Hodgson et al (2017) found that a quarter of ICU survivors had severe or moderate
26
27 disability at 6 months after discharge, and half of them had mild disability.[8] There
28
29 is no information to estimate how much the prevalence of disability increases
30
31 during a pandemic; however, the prevalence of mental health issues could be used
32
33 as a proxy of the expected impact on physical health. Hodgson et al (2017) found
34
35 that 22% of patients had anxiety or depressive symptoms at 6 months after
36
37 discharge. Lee et al (2007) found that among survivors of the SARS outbreak, 40%
38
39 had at least moderate anxiety one year after.[42] This is equivalent to a relative risk
40
41 of 1.81. Considering that measurement time points are different, we have
42
43 estimated our sample size assuming a relative risk (RR) of 1.5 or 1.6, which is
44
45 more conservative than the estimation based on the literature. The different
46
47 scenarios used for the sample size calculation appear in **Table 3**.
48
49
50
51
52
53
54
55
56
57
58
59
60

Table 3. Different plausible scenarios for sample size calculation

Outcome	Risk in non-pandemic situation	Risk during the pandemic	Type 1 error	Power	Sample size
WHODAS 2.0	25% severe or moderate disability	40% severe or moderate disability (RR=1.6)	0.05	0.8	343
WHODAS 2.0	40% some degree of disability	64% some degree of disability (RR=1.6)	0.05	0.8	288
WHODAS 2.0	50% mild disability	75% mild disability (RR=1.5)	0.05	0.8	388
HADS	22% anxiety or depressive symptoms	40% moderate anxiety (RR=1.8)	0.05	0.8	226

HADS, Hospital Anxiety and Depression Scale; RR, Relative Risk; WHODAS, World Health Organization Disability Assessment Schedule

The most plausible scenario is that 40% of ICU survivors discharged in a low demand period will have some degree of disability and this will increase to 64% for those discharged during high demand periods. Considering loss to follow-up, we estimate 550 patients need to be recruited at ICU discharge; so 413 patients are assessed at 3 months after discharge (25% loss to follow-up) and 289 patients at 6 months (30% lost to follow-up).

Quantitative analysis

Categorical variables will be presented as absolute and relative frequencies for each subgroup (i.e. admission diagnosis and treatment centre) and time point (i.e. ICU discharge, 3 and 6 months follow-up). In the case of normally distributed

1
2
3 continuous variables, these will be summarised using the mean and standard
4 deviation, while for those non-normally distributed, the median and interquartile
5 range will be used instead.
6
7

8
9
10 The trajectory for each outcome measure will be estimated using longitudinal
11 multilevel regression with robust standard errors to account for data coming from
12 seven treatment centres. The comparison according to periods of low and high
13 demand will be performed by adding an interaction term. If data have a normal
14 distribution, a linear regression model will be chosen. In the case of right skewed
15 data, a Poisson regression will be used. For HADS, IES-R and WHODAS 2.0, data
16 will be analysed as total scores and categories given by each questionnaire.
17
18

19 Survival will be analysed using Kaplan-Meier curves. If the assumption of
20 proportional hazards is met, survival will be compared between patients admitted
21 due to COVID-19 vs. other causes using Cox regression. All analyses will be
22 performed in Stata 16.0 SE.
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40

41 **Qualitative analysis**

42 Data from the interviews with family members and critical care staff will be
43 analysed using framework analysis.[43] Transcription will be aided by the software
44 Scrival and analysis by Nvivo 12.0. Two coders will listen and read in-full all
45 interviews before meeting to explore potential common topics that were discussed
46 during the interviews. These topics will form the initial coding framework. Through
47 an iterative process these codes will be refined into overarching themes capturing
48 differences and similarities across subgroups. A more advanced coding framework
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 will be reviewed with members of the research team until agreement regarding the
4
5 final framework is reached.
6

7 Themes will be used to explain the experience of family members during the
8
9 pandemic and, potentially, identify areas where improvements could be made in
10
11 the future. In the case of critical care staff, the aim is to explore to what extent the
12
13 approach to the pandemic of each centre influenced the experience of the different
14
15 clinical groups, and what can be learned for future outbreaks.
16
17

18 Findings will be shared with our participants and with other family members/ critical
19
20 care staff that did not participate in the interviews to ensure our interpretation
21
22 reflects their experiences.
23
24
25
26
27

28 **Patient and public involvement**

29 Patients or the public were not involved in the design, conduct, reporting, or
30
31 dissemination plans of this study.
32
33
34
35
36

37 **ETHICS AND DISSEMINATION**

38 **Ethical considerations**

39
40 The IMPACCT COVID-19 study is conducted in accordance with the Declaration of
41
42 Helsinki. Due to the observational nature of this study, patients will not be exposed
43
44 to any intervention, just observing the evolution of outcomes from ICU discharge to
45
46 6 months after. This study was reviewed and approved by the Clínica Alemana
47
48 Research and Clinical Trials Unit and the Facultad de Medicina Clínica Alemana
49
50 Universidad del Desarrollo Ethics Committee (registration number 2020-78). The
51
52 protocol was also reviewed and approved by each participating site ethics
53
54
55
56
57
58
59

1
2
3 committee. All recruited patients will be informed on the study obtaining their
4
5 written informed consent before the first evaluation. Patients will receive verbal and
6
7 written information related to post-intensive care syndrome at the ICU discharge
8
9 evaluation. At the 3- or 6-month evaluation patients with moderate or severe
10
11 disability (according to the WHODAS 2.0 results) will receive information on
12
13 rehabilitation alternatives at their nearest hospital.
14
15

16 17 18 19 **Dissemination**

20
21 We will disseminate results to key stakeholders including critical care clinicians,
22
23 patients, families, rehabilitation staff, research funders and the public.
24

25
26 The knowledge translation of the IMPACCT COVID-19 study will follow the three
27
28 end-of-grant knowledge translation strategy categories: *diffusion* (let it happen),
29
30 *dissemination* (help it happen) and *application* (make it happen).[44] *Diffusion* will
31
32 be carried out using social media such as Twitter and ResearchGate.
33

34
35 *Dissemination* will be carried out through presentation of findings in conference
36
37 meetings and peer-review journal publications following the Strengthening the
38
39 Reporting of Observational studies in Epidemiology (STROBE) guidelines.
40

41
42 Additionally, the progress, preliminary findings and final results will be
43
44 disseminated on the study's website ([https://medicina.udd.cl/kinesiologia-](https://medicina.udd.cl/kinesiologia-santiago/impacct)
45
46 [santiago/impacct](https://medicina.udd.cl/kinesiologia-santiago/impacct)). *Application* will include workshops, academic meetings and
47
48 development of useful tool for the follow-up of ICU survivors for both clinicians and
49
50 researchers.
51
52
53
54
55
56
57
58
59
60

REFERENCES

- 1 Herridge MS, Tansey CM, Matté A, *et al.* Functional disability 5 years after acute respiratory distress syndrome. *The New England journal of medicine* 2011;**364**:1293–304. doi:10.1056/NEJMoa1011802
- 2 Pfoh ER, Wozniak AW, Colantuoni E, *et al.* Physical declines occurring after hospital discharge in ARDS survivors: a 5-year longitudinal study. *Intensive Care Medicine* 2016;**42**:1557–66. doi:10.1007/s00134-016-4530-1
- 3 Van Aerde N, Meersseman P, Debaveye Y, *et al.* Five-year impact of ICU-acquired neuromuscular complications: a prospective, observational study. *Intensive Care Medicine* 2020;**46**:1184–93. doi:10.1007/s00134-020-05927-5
- 4 van Sleeuwen D, van de Laar F, Geense W, *et al.* Health problems among family caregivers of former intensive care unit (ICU) patients: an interview study. *BJGP Open* 2020;**4**:bjgpopen20X101061. doi:10.3399/bjgpopen20X101061
- 5 Griffiths J, Hatch RA, Bishop J, *et al.* An exploration of social and economic outcome and associated health-related quality of life after critical illness in general intensive care unit survivors: a 12-month follow-up study. *Critical Care* 2013;**17**:R100. doi:10.1186/cc12745
- 6 Martillo MA, Dangayach NS, Tabacof L, *et al.* Postintensive Care Syndrome in Survivors of Critical Illness Related to Coronavirus Disease 2019. *Critical Care Medicine* 2021;**Publish Ah**. doi:10.1097/CCM.0000000000005014
- 7 Huang C, Huang L, Wang Y, *et al.* 6-month consequences of COVID-19 in patients discharged from hospital: a cohort study. *The Lancet* 2021;**397**:220–32. doi:10.1016/S0140-6736(20)32656-8

- 1
2
3 8 Hodgson CL, Udy AA, Bailey M, *et al.* The impact of disability in survivors of
4 critical illness. *Intensive Care Medicine* 2017;**43**:992–1001.
5
6 doi:10.1007/s00134-017-4830-0
7
8
9
10 9 Hatch R, Young D, Barber V, *et al.* Anxiety, Depression and Post Traumatic
11 Stress Disorder after critical illness: a UK-wide prospective cohort study.
12
13 *Critical Care* 2018;**22**:310. doi:10.1186/s13054-018-2223-6
14
15
16
17 10 Pun BT, Badenes R, Heras La Calle G, *et al.* Prevalence and risk factors for
18 delirium in critically ill patients with COVID-19 (COVID-D): a multicentre
19 cohort study. *The Lancet Respiratory Medicine* 2021;**9**:239–50.
20
21
22 doi:10.1016/S2213-2600(20)30552-X
23
24
25
26 11 De Jonghe B, Sharshar T, Lefaucheur J-P, *et al.* Paresis acquired in the
27 intensive care unit: a prospective multicenter study. *JAMA* 2002;**288**:2859–
28
29 67. doi:10.1001/jama.288.22.2859
30
31
32
33 12 Organ System Support. NHS Digital.
34
35 2020.[https://www.datadictionary.nhs.uk/attributes/organ_system_supported.](https://www.datadictionary.nhs.uk/attributes/organ_system_supported.html)
36
37 [html](https://www.datadictionary.nhs.uk/attributes/organ_system_supported.html) (accessed 1 Aug 2020).
38
39
40 13 Needham DM, Sepulveda KA, Dinglas VD, *et al.* Core Outcome Measures
41 for Clinical Research in Acute Respiratory Failure Survivors: An International
42 Modified Delphi Consensus Study. *Am J Respir Crit Care Med* 2017;**;**1–42.
43
44
45
46
47 doi:10.1164/rccm.201702-0372OC
48
49 14 Turnbull AE, Sepulveda KA, Dinglas VD, *et al.* Core Domains for Clinical
50 Research in Acute Respiratory Failure Survivors. *Critical Care Medicine*
51
52 2017;**45**:1001–10. doi:10.1097/CCM.0000000000002435
53
54
55
56 15 World Health Organization. The International Classification of Functioning,
57
58
59
60

- 1
2
3 Disability and Health (ICF). Geneva, Switzerland: World Health Organization;
4
5 2001.
6
7
8 16 Organización Mundial de la Salud (OMS). *Medición de la Salud y la*
9
10 *Discapacidad: manual para el cuestionario de evaluación de la discapacidad*
11 *de la OMS: WHODAS 2.0*. 2015.
12
13
14 17 Rockwood K, Theou O. Using the Clinical Frailty Scale in Allocating Scarce
15
16 Health Care Resources. *Canadian geriatrics journal : CGJ* 2020;**23**:210–5.
17
18 doi:10.5770/cgj.23.463
19
20
21 18 Nakajima H, Nishikimi M, Shimizu M, *et al*. Clinical Frailty Scale Score
22
23 Before ICU Admission Is Associated With Mobility Disability in Septic
24
25 Patients Receiving Early Rehabilitation. *Critical Care Explorations*
26
27 2019;**1**:e0066. doi:10.1097/CCE.000000000000066
28
29
30 19 Geriatric Medicine Research of the Department of Medicine at Dalhousie
31
32 University. [https://www.dal.ca/sites/gmr/our-tools/clinical-frailty-scale/cfs-](https://www.dal.ca/sites/gmr/our-tools/clinical-frailty-scale/cfs-guidance.html)
33
34 [guidance.html](https://www.dal.ca/sites/gmr/our-tools/clinical-frailty-scale/cfs-guidance.html) (accessed 1 Aug 2020).
35
36
37 20 Vanpee G, Hermans G, Segers J, *et al*. Assessment of limb muscle strength
38
39 in critically ill patients: a systematic review. *Crit Care Med* 2014;**42**:701–11.
40
41
42 21 Hermans G, Clerckx B, Vanhullebusch T, *et al*. Interobserver agreement of
43
44 medical research council sum-score and handgrip strength in the intensive
45
46 care unit. *Muscle & Nerve* 2012;**45**:18–25. doi:10.1002/mus.22219
47
48
49 22 Huang M, Chan KS, Zanni JM, *et al*. Functional Status Score for the ICU: An
50
51 International Clinimetric Analysis of Validity, Responsiveness, and Minimal
52
53 Important Difference. *Critical care medicine* 2016;**44**:e1155–64.
54
55
56 doi:10.1097/CCM.0000000000001949
57
58
59

- 1
2
3 23 González-Seguel F, Leppe J, Hidalgo-Cabalín V, *et al.* Chilean version of the
4 Functional Status Score for the Intensive Care Unit: a translation and cross-
5 cultural adaptation. *Medwave* 2019;**19**:e7439–e7439.
6
7
8
9
10 doi:10.5867/medwave.2019.01.7439
11
12 24 Camus-Molina A, González-Seguel F, Castro-Ávila AC, *et al.* Construct
13 Validity of the Chilean-Spanish Version of the Functional Status Score for the
14 Intensive Care Unit: A Prospective Observational Study Using Actigraphy in
15 Mechanically Ventilated Patients. *Archives of Physical Medicine and*
16
17
18
19
20
21
22
23
24 25 Stienen MN, Geisseler O, Velz J, *et al.* Influence of the Intensive Care Unit
25 Environment on the Reliability of the Montreal Cognitive Assessment.
26
27
28
29
30
31 26 Delgado C, Araneda A, Behrens MI. Validación del instrumento Montreal
32 Cognitive Assessment en español en adultos mayores de 60 años.
33
34
35
36
37
38 27 Bello-Lepe S, Alonso-Sánchez MF, Ortega A, *et al.* Montreal Cognitive
39 Assessment as Screening Measure for Mild and Major Neurocognitive
40 Disorder in a Chilean Population. *Dementia and Geriatric Cognitive*
41
42
43
44
45
46
47 28 Jutte JE, Needham DM, Pfoh ER, *et al.* Psychometric evaluation of the
48 Hospital Anxiety and Depression Scale 3 months after acute lung injury.
49
50
51
52
53
54 29 Villoria E, Lara L. Assessment of the Hospital Anxiety and Depression Scale
55 for cancer patients. *Revista médica de Chile* 2018;**146**:300–7.
56
57
58
59
60

- 1
2
3 doi:10.4067/s0034-98872018000300300
4
5
6 30 Hosey MM, Bienvenu OJ, Dinglas VD, *et al.* The IES-R remains a core
7
8 outcome measure for PTSD in critical illness survivorship research. *Critical*
9
10 *Care* 2019;**23**:362. doi:10.1186/s13054-019-2630-3
11
12 31 Caamaño LW, Fuentes DM, González LB, *et al.* Adaptación y validación de
13
14 la versión chilena de la escala de impacto de evento-revisada (EIE-R).
15
16 *Revista Medica de Chile* 2011;**139**:1163–8. doi:10.4067/S0034-
17
18 98872011000900008
19
20
21 32 Oeyen SG, Vandijck DM, Benoit DD, *et al.* Quality of life after intensive care:
22
23 A systematic review of the literature. *Critical Care Medicine* 2010;**38**:2386–
24
25 400. doi:10.1097/CCM.0b013e3181f3dec5
26
27
28 33 EuroQol - a new facility for the measurement of health-related quality of life.
29
30 *Health Policy* 1990;**16**:199–208. doi:10.1016/0168-8510(90)90421-9
31
32
33 34 Zarate V, Kind P, Valenzuela P, *et al.* Social Valuation of EQ-5D Health
34
35 States: The Chilean Case. *Value in Health* 2011;**14**:1135–41.
36
37 doi:10.1016/j.jval.2011.09.002
38
39
40 35 Norman BC, Jackson JC, Graves JA, *et al.* Employment Outcomes After
41
42 Critical Illness. *Critical Care Medicine* 2016;**44**:2003–9.
43
44 doi:10.1097/CCM.0000000000001849
45
46
47 36 Kamdar BB, Suri R, Suchyta MR, *et al.* Return to work after critical illness: a
48
49 systematic review and meta-analysis. *Thorax* 2020;**75**:17–27.
50
51 doi:10.1136/thoraxjnl-2019-213803
52
53
54 37 Leppe J, Munizaga B, Margozzini P. Physical activity and sedentary behavior
55
56 according National Health Survey 2016-17. *Medwave* 2019;**19**:SP74.
57
58
59
60

- 1
2
3 doi:10.5867/medwave.2019.S1
4
5
6 38 Aguilar-Farias N, Leppe Zamora J. Is a single question of the Global Physical
7 Activity Questionnaire (GPAQ) valid for measuring sedentary behaviour in
8 the Chilean population? *Journal of Sports Sciences* 2016;;1–6.
9
10
11
12 doi:10.1080/02640414.2016.1229010
13
14
15 39 Kho ME, Molloy AJ, Clarke FJ, *et al.* TryCYCLE: A Prospective Study of the
16 Safety and Feasibility of Early In-Bed Cycling in Mechanically Ventilated
17 Patients. *PLOS ONE* 2016;**11**:e0167561. doi:10.1371/journal.pone.0167561
18
19
20
21 40 Thomas S, Mehrholz J. Health-related quality of life, participation, and
22 physical and cognitive function of patients with intensive care unit-acquired
23 muscle weakness 1 year after rehabilitation in Germany: the GymNAST
24 cohort study. *BMJ Open* 2018;**8**:e020163. doi:10.1136/bmjopen-2017-
25 020163
26
27
28
29
30
31
32
33 41 Nunna K, Al-Ani A, Nikooie R, *et al.* Participant Retention in Follow-Up
34 Studies of Acute Respiratory Failure Survivors. *Respiratory Care*
35 2020;**65**:1382–91. doi:10.4187/respcare.07461
36
37
38
39
40 42 Mehrholz J, Mückel S, Oehmichen F, *et al.* First results about recovery of
41 walking function in patients with intensive care unit-acquired muscle
42 weakness from the General Weakness Syndrome Therapy (GymNAST)
43 cohort study. *BMJ open* 2015;**5**:e008828. doi:10.1136/bmjopen-2015-008828
44
45
46
47
48
49 43 Braun V, Clarke V. Using thematic analysis in psychology. *Qualitative*
50 *Research in Psychology* 2006;**3**:77–101. doi:10.1191/1478088706qp063oa
51
52
53
54 44 Canadian Institutes of Health Research. Guide to Knowledge Translation
55 Planning at CIHR: Integrated and End-of-grant Approaches. 2012.www.cihr-
56
57
58
59
60

1
2
3 irsc.gc.ca/e/45321.html
4
5
6
7

8 **Collaborators:** The IMPACCT COVID-19 study group includes (organized
9
10 alphabetically): Ana Castro-Avila, Agustín Camus-Molina, Catalina Merino-Osorio,
11
12 Felipe González-Seguel and Jaime Leppe; and the following additional
13
14 collaborators: Camilo Cáceres Parra, Eduardo González Tapia, Felipe Muñoz-
15
16 Muñoz, Fernanda Baus Auil, Javiera Aguilera Scarpati, Joaquín Olave, Macarena
17
18 Leiva-Corvalán, Pilar Castro and Yerko Villagra Jofré.
19
20
21
22

23 **Contributors:** ACA, CMO, FGS and ACM contributed to the conception. ACA,
24
25 CMO, and FGS drafted the first version of the protocol manuscript. All authors
26
27 contributed to the study design and writing of the protocol. All authors reviewed the
28
29 manuscript and gave final approval of the version to be published.
30
31
32
33
34

35 **Acknowledgements:** We want to acknowledge the Universidad del Desarrollo for
36
37 funding this research and each participating site for allowing us to use part of their
38
39 infrastructure (organized alphabetically): *Clínica Alemana de Santiago, Clínica*
40
41 *BUPA, Clínica INDISA, Hospital del Salvador, Hospital Metropolitano, Hospital*
42
43 *Regional Dr. Leonardo Guzmán de Antofagasta, and Hospital San Pablo de*
44
45 *Coquimbo.*
46
47
48
49
50

51 **Funding:** IMPACCT COVID-19 study is funded by Universidad del Desarrollo
52
53 (Grant number 2020-78) and sponsored by the Chilean National Agency for
54
55
56
57
58
59
60

1
2
3 Research and Development (ANID-0772). The funders had no role in the design,
4 collection, analysis of the study, and writing of this manuscript.
5
6
7
8
9

10 **Competing interest:** None declare.
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

BMJ Open

Impact on Mental, Physical, And Cognitive functioning of a Critical Care sTay during the COVID-19 pandemic (IMPACCT COVID-19): protocol for a prospective, multicentre, mixed-methods cohort study

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2021-053610.R1
Article Type:	Protocol
Date Submitted by the Author:	26-Jul-2021
Complete List of Authors:	Castro-Avila, Ana; University of York, Health Sciences; Universidad del Desarrollo Facultad de Medicina Clínica Alemana, Carrera de Kinesiología Merino-Osorio, Catalina; Universidad del Desarrollo Facultad de Medicina Clínica Alemana, Carrera de Kinesiología González-Seguel, Felipe; Clinica Alemana de Santiago SA, Servicio Medicina Física y Rehabilitación; Universidad del Desarrollo Facultad de Medicina Clínica Alemana, Carrera de Kinesiología Camus-Molina, Agustín; Clinica Alemana de Santiago SA, Servicio Medicina Física y Rehabilitación; Universidad del Desarrollo, Facultad de Medicina Clínica Alemana Universidad del Desarrollo Leppe, Jaime; Universidad del Desarrollo Facultad de Medicina Clínica Alemana, Carrera de Kinesiología
Primary Subject Heading:	Intensive care
Secondary Subject Heading:	Intensive care, Rehabilitation medicine, Respiratory medicine
Keywords:	COVID-19, Adult intensive & critical care < ANAESTHETICS, REHABILITATION MEDICINE

SCHOLARONE™
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

1
2
3 **Title:** Impact on Mental, Physical, And Cognitive functioning of a Critical Care sTay
4 during the COVID-19 pandemic (IMPACCT COVID-19): protocol for a prospective,
5
6 multicentre, mixed-methods cohort study
7
8
9

10
11
12 **Abbreviated title:** IMPACCT COVID-19 study protocol
13
14

15
16
17 Ana Castro-Ávila, Catalina Merino-Osorio, Felipe González-Seguel, Agustín
18
19 Camus-Molina, Jaime Leppe, on behalf of the IMPACCT study group
20
21

22
23
24 Ana Castro-Ávila, PT, MSc, PhD, Department of Health Sciences, University of
25
26 York, Heslington, United Kingdom. Docente, Carrera de Kinesiología, Facultad de
27
28 Medicina Clínica Alemana Universidad del Desarrollo, Av. Plaza 680, Las Condes,
29
30 Santiago, Chile. <https://orcid.org/0000-0003-4475-4325>
31
32

33
34
35 Catalina Merino-Osorio, PT, MSc, Carrera de Kinesiología, Facultad de Medicina
36
37 Clínica Alemana Universidad del Desarrollo, Av. Plaza 680, Las Condes, Santiago,
38
39 Chile. <https://orcid.org/0000-0002-6836-5466>
40
41

42
43
44 Felipe González-Seguel, PT, MSc, Servicio de Medicina Física y Rehabilitación,
45
46 Departamento de Medicina Interna, Facultad de Medicina Clínica Alemana
47
48 Universidad del Desarrollo, Av. Vitacura 5951, Santiago, Chile.
49
50
51 <https://orcid.org/0000-0001-9099-2389>
52
53

54 Address all correspondence at: feligonzales@udd.cl +(56) 9 89540683.
55
56
57
58
59
60

1
2
3 Agustín Camus-Molina, PT, MSc, Servicio de Medicina Física y Rehabilitación,
4
5 Departamento de Medicina Interna, Facultad de Medicina Clínica Alemana
6
7 Universidad del Desarrollo, Av. Vitacura 5951, Santiago, Chile.
8
9

10 <https://orcid.org/0000-0001-7378-9565>
11
12
13

14 Jaime Leppe, PT, MSc, Carrera de Kinesiología, Facultad de Medicina Clínica
15
16 Alemana Universidad del Desarrollo, Av. Plaza 680, Las Condes, Santiago, Chile.
17
18

19 <https://orcid.org/0000-0002-8663-1182>
20
21
22

23
24 **Number of figures:** 1
25

26 **Reference Mendeley Style:** BMJ Open
27

28 **Word count** (excluding title page, abstract, references, figures, tables and
29
30 strengths and limitations): 3540/4000
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

ABSTRACT (291/300)

Introduction The ongoing pandemic could affect the duration, variety, and severity of the mental, cognitive, and physical impairments intensive care unit (ICU) survivors and their families frequently present. We aim to determine the impact of the COVID-19 pandemic on the physical, mental, and cognitive health of survivors, the experience of their families and their treating healthcare professionals.

Methods and analysis: Prospective, multicentre, mixed-methods cohort study in seven Chilean ICUs. Sample: 450 adults, able to walk independently prior to admission, in ICU and mechanical ventilation >48 hours with and without COVID-19. Clinical Frailty Scale, Charlson comorbidity index, mobility (FSS-ICU) and muscle strength (MRC-SS) will be assessed at ICU discharge. Cognitive functioning (MOCA-blind), anxiety and depression (HADS), post-traumatic stress (IES-R) symptoms, disability (WHODAS 2.0), quality of life (EQ-5D-3L), employment, and survival will be assessed at ICU discharge, 3 and 6 months. A sample will be assessed using actigraphy and the Global Physical Activity Questionnaire at 6 months after ICU discharge. Trajectories of physical, mental and cognitive impairments will be estimated using multilevel longitudinal modelling. A sensitivity analysis using multiple imputations will be performed to account for missing data and loss-to-follow-up. Survival will be analysed using Kaplan-Meier curves. The perceptions of family members regarding the ICU stay and the later recovery will be explored 3 months after discharge. Healthcare professionals will be invited to discuss the challenges faced during the pandemic using semi-structured interviews. Interviews will be thematically analysed by two independent

coders to identify the main themes of the experience of family members and healthcare professionals.

Ethics and dissemination: The study was approved by the Clinica Alemana Universidad del Desarrollo Ethics Committee (2020-78) and each participating site. Study findings will be published in peer-reviewed journals and disseminated through social media and conference meetings.

Keywords: COVID-19, critical care, postintensive care syndrome, rehabilitation, follow-up studies

Strengths and limitations of this study:

- This is the first Chilean multicentre study assessing post-ICU sequelae.
- Experiences of family members and health care professionals during the pandemic will also be explored.
- Due to infection control protocols and lockdowns, most physical functioning measures are self-reported.
- Patient's ICU assessments were limited by increased workload and restrictions in access to the ICUs.

INTRODUCTION

Post-intensive care syndrome (PICS) is a common consequence of an intensive care unit (ICU) stay and can last up to 5 years.[1–3] The family members are often affected, reporting diminished quality of life and mental health related quality of life.[4] About 80% of family members become informal carers and 33% of families

1
2
3 see a significant reduction of income the first 6 months after discharge.[5] The
4 extent to which these problems will be modified by the coronavirus disease 2019
5 (COVID-19) pandemic remains unknown.
6
7

8
9
10 If under normal circumstances, an ICU stay has detrimental effects, the pandemic
11 added three extra factors. Firstly, a rapid and exponential increase in acute care
12 bed capacity might have affected the quality of care delivered by spreading too thin
13 highly skilled healthcare staff. Secondly, COVID-19 involves a new disease with
14 great uncertainties regarding treatment, prognosis and long-term effects. Early
15 reports suggest that 64% of patients who were discharged from ICU after COVID-
16 19 have at least one symptom of PICS at 6 months after discharge[6] and 32% had
17 anxiety or depression symptoms,[7] which suggests these patients will have similar
18 impairments to what has been reported for other ICU survivors previously.[8,9]
19
20 Thirdly, infection control protocols meant that healthcare staff had to wear personal
21 protective equipment and family visiting was restricted.[10] These factors add
22 another layer of potential negative effects due to challenges in communication with
23 patients and their family members. Therefore, we hypothesize that the prevalence
24 and severity of mental, physical, and cognitive impairments will be higher in
25 patients treated in periods of higher bed occupancy and those who had COVID-19.
26
27 In the case of family members, we expect that the experience of having a next of
28 kin in the ICU during the pandemic would be stressful and traumatic, but those with
29 social support will cope better as the stress process model suggests[11]. In the
30 case of staff members, their experiences will vary greatly depending on their
31 profession and workplace, but we expect places with a more open/ less
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 hierarchical structure to have coped better with the increase in demand because
4 they adapt faster to change[12].
5
6

7
8 The primary objective of this study is to compare the trajectory of mental, physical
9 and cognitive impairments at ICU discharge, 3 and 6 months of mechanically
10 ventilated adult patients who survived an ICU stay due to COVID-19 or other
11 causes during high and low bed occupancy in the pandemic. Secondary objectives
12 are:
13
14
15
16
17
18

- 19 ● To compare the employment status, quality of life and survival rate at ICU
20 discharge, 3 and 6 months of patients who were admitted to ICU due to
21 COVID-19 or other causes during high and low bed occupancy in the
22 pandemic;
23
24
25
26
27
- 28 ● To describe the sedentary behaviour and physical activity levels in a sample
29 of ICU survivors during the COVID-19 pandemic using a one-week
30 actigraphy protocol;
31
32
33
34
- 35 ● To explore the psychological and emotional experiences reported by family
36 members/next of kin of patients admitted to the ICU during the COVID-19
37 pandemic;
38
39
40
41
- 42 ● To explore the emotional, intellectual, physical and administrative
43 challenges faced by the participating ICU staff during the COVID-19
44 pandemic;
45
46
47
48
- 49 ● To evaluate the feasibility of the follow-up from ICU discharge to 3 and 6
50 months during the pandemic.
51
52
53
54
55
56
57
58
59
60

METHODS

Study design and setting

The “Impact on Mental, Physical, And Cognitive functioning of a Critical Care sTay during the COVID-19 pandemic” (IMPACCT COVID-19) is a prospective, multicentre, cohort study in seven Chilean academic medical-surgical ICUs. This study also involves a qualitative component including semi-structured interviews with family members/next of kin of ICU survivors and with ICU staff from the participating centres. Participating sites are four public and three private hospitals comprising a pooled bed capacity of about 200 ICU beds for both COVID-19 patients and patients admitted for other causes. The IMPACCT COVID-19 study started in October 2020 and the initial recruitment at ICU discharge has ended. Data collection is planned until November 2021 to achieve completion of the study in February 2022.

Study population and eligibility criteria

Within 72 hours after ICU discharge, adult patients (≥ 18 years old) who are mechanically ventilated for at least 48 hours in one of the participating ICUs and do not meet any of the exclusion criteria (**Table 1**) will be invited to participate.

Table 1. Exclusion and stopping follow-up criteria

Exclusion criteria	Rationale
Unable to walk independently 2 weeks prior to ICU admission (with or without a gait aid)	Potential confounding factor
S5q < 5 or CAM-ICU positive within 72 hours after ICU discharge	Unable to evaluate
Patient who do not understand or speak Spanish	Unable to evaluate
Patient unable to communicate verbally	Incomplete assessment data
Burn or severe trauma as admission diagnosis	Incomplete assessment data
Any neurological disorder (i.e. spinal cord injury, stroke and brain tumours) as admission diagnosis	Potential confounding factor
Transferred to a non-participating study centre before ICU discharge assessment	Unable to evaluate
Recent prolonged hospital stay (extended by more than 3 months)	Potential confounding factor
Criteria to stop follow-up	
Re-admission after being ICU discharged	Potential confounding factor
Withdrawal of consent	Incomplete assessment data
Death before 3 or 6 months from ICU discharge	Incomplete assessment data

CAM-ICU, Confusion Assessment Method for the Intensive Care Unit; ICU, intensive care unit; s5q, Standardized Five Questions

Procedure

The planned flow of participants throughout the study is presented in **Figure 1**.

Patients will be screened daily to identify those that are in conditions for ICU discharge. Each site coordinator, which is a clinician physiotherapist responsible for the site, will check that the patient is delirium-free (CAM-ICU negative) and cooperative (i.e. using 5 standardised questions: open [close] your eyes; look at me; open your mouth and stick out your tongue; nod your head; raise your eyebrows when I have counted up to five[13]) within 72 hours from ICU discharge.

Every patient deemed eligible will be invited to participate through a face-to-face visit by the assigned evaluator, receiving verbal and written information about the study. Patients will be assessed at ICU discharge (T1, defined by the point between medical decision of discharge until 72 hours after), 3 months (T2) and 6 months after ICU discharge (T3). Fifty-eight physiotherapists were trained for the assessments at ICU discharge, which included in-person measurements and self-administered questionnaires. Physiotherapists had to be working in one of the participating ICUs at the time of the training. Training for standardising T1 assessments was delivered by experienced physiotherapists and researchers (ACM, CMO and FGS). For the follow-up assessments (T2 and T3), patients will be contacted via email or telephone to schedule a phone call evaluation performed by trained interviewers. Additionally, physical activity and sedentary behaviour will be assessed using actigraphy 6 months after ICU discharge in a sample of participants (details described below).

After the patient agreed to participate and signed the informed consent form, the following baseline data will be collected from the patient clinical records: age, gender, body mass index (BMI), highest educational level achieved (no formal education, primary school, secondary school, undergraduate or postgraduate), admission diagnosis, Charlson Comorbidity Index, duration of mechanical ventilation, length of hospital stay before ICU admission, ICU length of stay, number of intubations and the maximum level of organ system support received.[14]

Measurement Outcomes

The assessment points and measurement instruments are presented in **Table 2**. Measurement instruments were selected according to the recommended Core Outcome Measurement Set for critical illness survivors.[15,16]

Table 2. Schedule of enrolment and follow-up of the IMPACCT COVID-19 study

	Study period		
	Enrolment	Follow-up	
	ICU discharge	3 months from enrolment	6 months from enrolment
Eligibility screening			
Inclusion and exclusion	X		
Invitation to participate			
Informed consent	X		
Patient characteristics			
Age, gender, BMI	X		
Data related to hospitalisation			
Diagnosis, MV days, ICU LOS	X		
Maximum level of organ system support	X		
Pre-admission health and functioning			
Charlson Comorbidity Index	X		
Educational level	X		
Employment status	X	X	X

Clinical Frailty Scale	X	X	X
Physical functioning			
MRC Sum Score	X		
FSS-ICU	X		
Cognitive functioning			
MoCA blind	X	X	X
Mental functioning			
IES-R	X	X	X
HADS	X	X	X
Disability and quality of life			
WHODAS 2.0	X	X	X
EQ-5D-3L		X	X
Sedentary behaviour and physical activity			
Actigraphy			X
GPAQ			X
Survival rate	X	X	X

BMI, body mass index; EQ-5D-3L, European Quality of Life Health Questionnaire 5 domains; FSS-ICU, Functional Status Score for the Intensive Care Unit; GPAQ, Global Physical Activity Questionnaire; HADS, Hospital Anxiety and Depression Scale; ICU, intensive care unit; IES-R, Impact of Event Scale Revised; IMPACCT COVID-19, Impact on Mental, Physical, And, Cognitive functioning of Critical care Time due to COVID-19; LOS, length of stay; MoCA, Montreal Cognitive Assessment; MRC, Medical Research Council; MV, mechanical ventilation; WHODAS, World Health Organization Disability Assessment Schedule

When available, we used the Chilean version of each instrument, otherwise, the validated version in Spanish. Trained physiotherapists will take an estimated maximum time of 70 minutes to perform the assessment at ICU discharge (T1). A trained interviewer will take an estimated maximum time of 20 minutes to apply the questionnaires by telephone at 3 (T2) and 6 months (T3) after ICU discharge.

The primary outcome measure is disability assessed at 6 months after ICU discharge using the World Health Organization Disability Assessment Schedule 2.0 (WHODAS 2.0) which is recommended for critical illness survivors.[8] The WHODAS 2.0 is a self-reported disability questionnaire based on the International Classification of Functioning, Disability, and Health (ICF). It includes 36 questions,

1
2
3 organised under six domains (cognition, mobility, self-care, getting along, life
4 activities and participation). Each question must be answered based on the
5 perceived difficulty for performing activities using a 5-point scale (none, mild,
6 moderate, severe and extreme).[17] We will use the Spanish version freely
7 available at <https://apps.who.int/iris/handle/10665/170500>. [18] The estimated
8 response time ranges from 5 to 10 minutes when evaluated in-person at ICU
9 discharge and 10 to 20 minutes when evaluated by telephone at 3 and 6 months
10 after ICU discharge.
11
12
13
14
15
16
17
18
19
20
21
22

23 Secondary outcomes measures

24 *Clinical Frailty Scale*

25
26 The Clinical Frailty Scale (CFS) is a clinical judgment based tool developed for the
27 Canadian Study of Health and Aging to evaluate the degree of frailty in elderly
28 patients.[19] Currently, it is also used for critically ill patients.[20] The CFS
29 evaluates specific domains including physical functioning, activities of daily living
30 (ADL), instrumental ADL, assistance for personal care, comorbidities, and
31 cognition to generate a frailty score using a 9-point scale ranging from 1 (very fit) to
32 9 (terminally ill). A score greater than 4 is considered fragile.[19] We will use the
33 Spanish version and recommended training material by the developers at the
34 Dalhousie University.[19,21] The estimated scoring time ranges from 1 to 5
35 minutes evaluated in-person at ICU discharge considering the status 2 weeks
36 before the onset of symptoms.
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Medical Research Council Sum Score (MRC-SS)

Limb muscle strength will be assessed using the MRC-SS, which consists in a standardised examination of six muscle groups bilaterally (i.e. shoulder abduction, elbow flexion, wrist extension, hip flexion, knee extension and dorsiflexion).[22] All muscle groups are scored using a 6-point scale between 0 and 5 (0 = no visible / palpable contraction; 1 = visible / palpable contraction or no limb movement; 2 = limb movement, but not against gravity; 3 = movement against the gravity over nearly the entire range of motion; 4 = motion against gravity and resistance, subjectively adjusted for gender and age; 5 = normal force). This scale requires an estimated assessment time of 5 to 10 minutes and will be evaluated only at ICU discharge following the method described by Hermans *et al.*[23]

Functional Status Score for the Intensive Care Unit (FSS-ICU)

The FSS-ICU is a mobility instrument to score the level of physical assistance required when performing five functional activities: rolling, transfer from supine to sit, sitting at the edge of the bed, transfer from sitting to stand, and walking.[24] Each activity is scored using a 7-point scale ranging from 0 (not able to perform) to 7 (complete independence). The resulting overall score ranges from 0 to 35 points. Each evaluation requires between 10 and 30 minutes. It will be assessed at ICU discharge using the available and validated Chilean version.[25,26] Due to the limitations during the pandemic, walking will be evaluated inside the room, occasionally forcing the patient to walk with more laps than usual.

Montreal Cognitive Assessment–Blind (MoCA blind)

The MoCA blind is a cognitive screening tool designed to detect cognitive dysfunction in five areas: memory, attention, language, abstraction and orientation. It requires 5 minutes to be completed.[27] Each domain is scored separately for a total score ranging from 0 to 22 points. A score equal to or greater than 18 points is considered normal cognition. To minimize memory bias, the MoCA blind will be assessed using version 7.1 at ICU discharge (in-person), version 7.2 at 3 months (by telephone) and version 7.3 at 6 months (by telephone),[28,29]. One evaluator (ACM) received training and certification by Test MoCA Inc., and then trained the rest of the evaluators following the standardised procedure available at <https://www.mocatest.org>. As recommended by the developers, the results of this test will not be used for diagnostic purposes, but as a cognitive screening.

Hospital Anxiety and Depression Scale (HADS)

The HADS is an interviewer or self-administered questionnaire designed to identify anxiety and depressive symptoms in a wide variety of in-hospital patients, which requires between 2 and 5 minutes to be completed.[30] The HADS has fourteen questions, seven for anxiety and seven for depressive symptoms. Each question is rated with a 4-point scale ranging from 0 ("absence") to 3 ("extreme presence"), resulting in a sum score of 21 points per subscale. HADS will be evaluated at ICU discharge and by telephone at 3 and 6 months using the Chilean version.[31]

Impact of Events Scale–Revised (IES-R)

The IES-R is an interviewer or self-administered questionnaire designed to measure the subjective distress caused by traumatic events that has been validated for critical illness survivors.[32] It comprises 22 questions divided in three subscales: intrusion, avoidance, and hyperarousal. Questions are rated in a 5-point scale ranging from 0 ("not at all") to 4 ("extremely"). The estimated response time is 6 minutes. It will be evaluated at ICU discharge and by telephone at 3 and 6 months using the available Chilean version.[33]

European Quality of Life Health Questionnaire (EQ-5D-3L)

The EQ-5D-3L is an interviewer or self-administered questionnaire of health status or health-related quality of life, including five domains: mobility, self-care, usual activities, pain/discomfort, anxiety/depression and global health state.[34,35] Each domain is scored based on 3 levels of severity: no problems, some problems, and extreme problems. Additionally, EQ-5D-3L includes a Visual Analog Scale ranging from "best imaginable health state" (100) to "worst imaginable health state" (0). Both parts of the questionnaire take an estimated response time of 2 minutes. It will be evaluated by telephone at 3 and 6 months using the Chilean version.[36]

Employment status

The employment status will be evaluated at ICU discharge, 3 and 6 months using tailored questions regarding current occupation, working hours, and any changes to their employment situation as it has been used elsewhere.[37,38]

Survival

The survival rate will be measured by the percentage of patients still alive at ICU discharge, 3 months, and 6 months after ICU discharge. Information on deaths will be obtained from death certificates from the Chilean National Civil Registry.

Sedentary Behaviour and Physical Activity

Sedentary behaviour and physical activity will be measured using a standardized one-week actigraphy protocol according to the Chilean National Health Survey [39,40] using the ActiGraph GT3X (ActiGraph, Pensacola, FL, USA) accelerometer and the Global Physical Activity Questionnaire (GPAQ). We will invite all participants at the three-month follow-up phone call. Among those who agree to participate, we will recruit participants to achieve maximum variation in terms of age, sex, and duration of mechanical ventilation aiming to recruit at least 100 participants. The measurements will be conducted at 6 months after ICU discharge.

Family or next of kin interviews

During the 3-month follow-up call, patients will be asked if a family member or next of kin will be willing to participate in the interview study. Once monthly, we will purposely select a sample of family members to be contacted. The selection will be performed to ensure maximum variation in terms of age, educational level, length of ICU stay, treatment centre and COVID-19 status of the patient that went through ICU. Information about the interview study will be provided over the phone following a script approved by the ethics committee. Once the family members

1
2
3 verbally consent, the interview will be scheduled. Interviews will be semi-structured
4
5 and be recorded for later transcription verbatim. The interviewer is a clinical
6
7 psychologist with experience conducting interviews and training on providing
8
9 emotional support for people under distress. We will aim to conduct 18 interviews
10
11 or more until data saturation is achieved. Interviews will cover four main topic
12
13 areas: ICU admission, communication during the ICU stay, experience of returning
14
15 home, and the experience of having a loved one in the ICU (Supplementary file).
16
17 Each transcription will be anonymised, and the recording will be securely deleted.
18
19
20
21
22

23 **Critical care staff interviews**

24
25
26 Once the bed occupancy in ICU returns to usual levels, recruitment will start. An
27
28 open call to participate will be made through WhatsApp and Facebook groups of
29
30 the clinicians working in the participating centres. Additionally, posters will be put in
31
32 the rest areas to capture a wider population. We will recruit medics, nurses,
33
34 healthcare assistants and physiotherapists that normally work in an ICU and have
35
36 patient-facing clinical duties for more than 96 hours during the pandemic. The
37
38 invitation to participate will lead to a Google form containing information about the
39
40 study and a short script that constitutes the informed consent. From the list of
41
42 volunteers, we will purposely sample three professionals per clinical group aiming
43
44 to maximise variation regarding years of experience and centre where they work.
45
46 We expect a minimum of 40 interviews, but we will continue recruitment until data
47
48 saturation is achieved. Interviews will be conducted online or over the phone.
49
50
51 Participants will be asked for verbal consent before starting the interview, which will
52
53
54 be recorded for later transcription verbatim. Interviews will be semi-structured
55
56
57
58
59
60

1
2
3 covering five main topic areas: preparation before the pandemic; intellectual,
4 physical and emotional challenges during the pandemic; and learning for future
5 events (Supplementary file).
6
7
8
9

10 11 12 **Follow-up feasibility** 13

14 The consent rate will be collected, calculating the number of patients who agreed
15 to participate divided by the number of patients who meet selection criteria,
16 expecting a consent rate > 70%.[41] The feasibility over-time during the follow-up
17 will be measured as cohort retention rate, considering the number of patients who
18 can be contacted and evaluated at 3 and 6 months, expecting a cohort retention
19 rate > 70% as elsewhere.[42–44] Additionally, the reasons for the lack of
20 assessments will be recorded individually.
21
22
23
24
25
26
27
28
29
30
31
32

33 **Sample size calculation** 34

35 All patients meeting the eligibility criteria discharged from ICU between October
36 2020 and April 2021 (due to funding constraints) will be invited to participate.
37 Based on bed capacity and patient flow from previous years, we estimated that 20
38 to 30 mechanically ventilated adult patients are discharged monthly from each
39 centre. This means the sampling universe ranges from 840 to 1260 patients.
40 Hodgson et al (2017) found that a quarter of ICU survivors had severe or moderate
41 disability at 6 months after discharge, and half of them had mild disability.[8] There
42 is no information to estimate how much the prevalence of disability increases
43 during a pandemic; however, the prevalence of mental health issues could be used
44 as a proxy of the expected impact on physical health. Hodgson et al (2017) found
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

that 22% of patients had anxiety or depressive symptoms at 6 months after discharge. Lee et al (2007) found that among survivors of the SARS outbreak, 40% had at least moderate anxiety one year after.[42] This is equivalent to a relative risk of 1.81. Considering that measurement time points are different, we have estimated our sample size assuming a relative risk (RR) of 1.5 or 1.6, which is more conservative than the estimation based on the literature. The different scenarios used for the sample size calculation appear in **Table 3**.

Table 3. Different plausible scenarios for sample size calculation

Outcome	Risk in non-pandemic situation	Risk during the pandemic	Type 1 error	Power	Overall estimated sample size
WHODAS 2.0	25% severe or moderate disability	40% severe or moderate disability (RR=1.6)	0.05	0.8	343
WHODAS 2.0	40% some degree of disability	64% some degree of disability (RR=1.6)	0.05	0.8	288
WHODAS 2.0	50% mild disability	75% mild disability (RR=1.5)	0.05	0.8	388
HADS	22% anxiety or depressive symptoms	40% moderate anxiety (RR=1.8)	0.05	0.8	226

HADS, Hospital Anxiety and Depression Scale; RR, Relative Risk; WHODAS, World Health Organization Disability Assessment Schedule

The most plausible scenario is that 40% of ICU survivors discharged in a low demand period will have some degree of disability and this will increase to 64% for those discharged during high demand periods. Considering loss to follow-up, we

1
2
3 estimate a total of 550 patients need to be recruited at ICU discharge; so 413
4
5 patients are assessed at 3 months after discharge (25% loss to follow-up) and 289
6
7 patients at 6 months (30% lost to follow-up).
8
9

10 11 12 **Quantitative analysis**

13
14 Categorical variables will be presented as absolute and relative frequencies for
15
16 each subgroup (i.e. admission diagnosis and treatment centre) and time point (i.e.
17
18 ICU discharge, 3 and 6 months follow-up). In the case of normally distributed
19
20 continuous variables, these will be summarised using the mean and standard
21
22 deviation, while for those non-normally distributed, the median and interquartile
23
24 range will be used instead.
25
26

27
28 The trajectory for each outcome measure will be estimated using longitudinal
29
30 multilevel regression with robust standard errors to account for data coming from
31
32 seven treatment centres. The comparison according to periods of low and high
33
34 demand will be performed by adding an interaction term. All models will be
35
36 adjusted for age, sex, duration of mechanical ventilation, and the Charlson
37
38 Comorbidity Index. If data have a normal distribution, a linear regression model will
39
40 be chosen. In the case of right skewed data, a Poisson regression will be used. For
41
42 HADS, IES-R and WHODAS 2.0, data will be analysed as total scores and
43
44 categories given by each questionnaire. Longitudinal multilevel modelling is robust
45
46 to missing values when these are missing at random. We will test for this
47
48 assumption by comparing age, sex, duration of mechanical ventilation, and the
49
50 Charlson Comorbidity Index of patients loss-to-follow-up and those that were
51
52 assessed at all time points. If the assumption is not met, we will use a regression
53
54
55
56
57
58
59
60

1
2
3 model to estimate the score values of patients with similar characteristics regard
4
5 the four variables aforementioned.
6

7 Survival will be analysed using Kaplan-Meier curves. If the assumption of
8
9 proportional hazards is met, survival will be compared between patients admitted
10
11 due to COVID-19 vs. other causes using Cox regression. The Bonferroni correction
12
13 for multiple testing will be used to adjust p-values. All analyses will be performed in
14
15 Stata 16.0 SE.
16
17
18
19
20
21

22 **Qualitative analysis**

23
24
25 Data from the interviews with family members and critical care staff will be
26
27 analysed using framework analysis.[45] Transcription will be aided by the software
28
29 Scrival and analysis by Nvivo 12.0. Two coders will listen and read in-full all
30
31 interviews before meeting to explore potential common topics that were discussed
32
33 during the interviews. These topics will form the initial coding framework. Through
34
35 an iterative process these codes will be refined into overarching themes capturing
36
37 differences and similarities across subgroups. A more advanced coding framework
38
39 will be reviewed with members of the research team until agreement regarding the
40
41 final framework is reached.
42
43
44

45
46 Themes will be used to explain the experience of family members during the
47
48 pandemic and, potentially, identify areas where improvements could be made in
49
50 the future. In the case of critical care staff, the aim is to explore to what extent the
51
52 approach to the pandemic of each centre influenced the experience of the different
53
54 clinical groups, and what can be learned for future outbreaks.
55
56
57
58
59
60

1
2
3 Findings will be shared with our participants and with other family members/ critical
4
5 care staff that did not participate in the interviews to ensure our interpretation
6
7 reflects their experiences.
8
9

10 11 12 **Patient and public involvement** 13

14 Patients or the public were not involved in the design, conduct, reporting, or
15
16 dissemination plans of this study.
17
18

19 20 21 **DISCUSSION** 22

23 To the best of our knowledge, this is the first Chilean multicentre study assessing
24
25 functional outcomes related to PICS in mechanically ventilated patients using the
26
27 Core Outcome Measurement Set for critical illness survivors. The findings of this
28
29 study will help determine the effect of the current pandemic in the prevalence of
30
31 PICS in ICU survivors treated in public and private hospitals in Chile. This study
32
33 will also explore experiences of family members/carers and health care
34
35 professionals working during the current pandemic. Learnings regarding how to
36
37 improve recruitment of participants, the practicalities of data collection during a
38
39 pandemic, and strategies to reduce/prevent attrition will be helpful for future cohort
40
41 studies in the country and elsewhere.
42
43
44
45
46
47
48

49 **Limitations** 50

51 This study is not exempt of limitations. Firstly, the pandemic imposes conditions
52
53 that we cannot control for. Localised lockdowns affected differently the participating
54
55 hospitals; therefore, it could not be predicted whether the follow-up of these
56
57
58
59
60

1
2
3 patients could include face-to-face assessments or not due to the risk of infection
4
5 and legal restrictions. Additionally, leaves of absence due to sickness and being a
6
7 close contact of a COVID-19 case meant that the skill mix and workload of the
8
9 healthcare professionals varied widely in each unit and day-to-day.
10

11
12 Secondly and related to the uncertainty of conducting face-to-face measurements,
13
14 we designed this study to include self-reported at 3 and 6 months after ICU
15
16 discharge. This means we were unable to perform the Six Minute Walking Test
17
18 [46], which is a recommended measure of physical functioning. Instead, we will
19
20 collect self-reported measures such as the EQ-5D and WHODAS 2.0, which can
21
22 be assessed over the phone. Additionally, we will assess in a subsample physical
23
24 activity using actigraphy, which will provide valuable information about sedentary
25
26 behaviours of ICU survivors. Thirdly, the variables and assessments collected at
27
28 baseline are a balance between building a comprehensive picture of the physical,
29
30 mental, and cognitive state of each participant and what was a reasonable time
31
32 commitment for the healthcare professionals working during the pandemic.
33
34
35
36
37
38
39

40 **ETHICS AND DISSEMINATION**

41 **Ethical considerations**

42
43 The IMPACCT COVID-19 study is conducted in accordance with the Declaration of
44
45 Helsinki. Due to the observational nature of this study, patients will not be exposed
46
47 to any intervention, just observing the evolution of outcomes from ICU discharge to
48
49 6 months after. This study was reviewed and approved by the Clínica Alemana
50
51 Research and Clinical Trials Unit and the Facultad de Medicina Clínica Alemana
52
53 Universidad del Desarrollo Ethics Committee (registration number 2020-78) and
54
55
56
57
58
59

1
2
3 the Servicio de Salud Metropolitano Oriente Ethics Committee (registration number
4 152-0029). The protocol was also reviewed and approved by the clinical director of
5
6 152-0029). The protocol was also reviewed and approved by the clinical director of
7
8 each participating ICU department. All recruited patients will be informed on the
9
10 study obtaining their written informed consent before the first evaluation. Patients
11
12 will receive verbal and written information related to post-intensive care syndrome
13
14 at the ICU discharge evaluation. At the 3- or 6-month evaluation patients with
15
16 moderate or severe disability (according to the WHODAS 2.0 results) will receive
17
18 information on rehabilitation alternatives at their nearest hospital.
19
20
21
22
23

24 **Dissemination**

25
26 We will disseminate results to key stakeholders including critical care clinicians,
27
28 patients, families, rehabilitation staff, research funders and the public.
29

30
31 The knowledge translation of the IMPACCT COVID-19 study will follow the three
32
33 end-of-grant knowledge translation strategy categories: *diffusion* (let it happen),
34
35 *dissemination* (help it happen) and *application* (make it happen).[47] *Diffusion* will
36
37 be carried out using social media such as Twitter and ResearchGate.

38
39
40 *Dissemination* will be carried out through presentation of findings in conference
41
42 meetings and peer-review journal publications following the Strengthening the
43
44 Reporting of Observational studies in Epidemiology (STROBE) guidelines.
45

46
47 Additionally, the progress, preliminary findings and final results will be
48
49 disseminated on the study's website ([https://medicina.udd.cl/kinesiologia-](https://medicina.udd.cl/kinesiologia-santiago/impacct)
50
51 [santiago/impacct](https://medicina.udd.cl/kinesiologia-santiago/impacct)). *Application* will include workshops, academic meetings and
52
53 development of useful tool for the follow-up of ICU survivors for both clinicians and
54
55 researchers.
56
57
58
59
60

REFERENCES

- 1 Herridge MS, Tansey CM, Matté A, *et al.* Functional disability 5 years after acute respiratory distress syndrome. *N Engl J Med* 2011;**364**:1293–304. doi:10.1056/NEJMoa1011802
- 2 Pfoh ER, Wozniak AW, Colantuoni E, *et al.* Physical declines occurring after hospital discharge in ARDS survivors: a 5-year longitudinal study. *Intensive Care Med* 2016;**42**:1557–66. doi:10.1007/s00134-016-4530-1
- 3 Van Aerde N, Meersseman P, Debaveye Y, *et al.* Five-year impact of ICU-acquired neuromuscular complications: a prospective, observational study. *Intensive Care Med* 2020;**46**:1184–93. doi:10.1007/s00134-020-05927-5
- 4 van Sleeuwen D, van de Laar F, Geense W, *et al.* Health problems among family caregivers of former intensive care unit (ICU) patients: an interview study. *BJGP Open* 2020;**4**:bjgpopen20X101061. doi:10.3399/bjgpopen20X101061
- 5 Griffiths J, Hatch RA, Bishop J, *et al.* An exploration of social and economic outcome and associated health-related quality of life after critical illness in general intensive care unit survivors: a 12-month follow-up study. *Crit Care* 2013;**17**:R100. doi:10.1186/cc12745
- 6 Martillo MA, Dangayach NS, Tabacof L, *et al.* Postintensive Care Syndrome in Survivors of Critical Illness Related to Coronavirus Disease 2019. *Crit Care Med* 2021;**Publish Ah**. doi:10.1097/CCM.0000000000005014
- 7 Huang C, Huang L, Wang Y, *et al.* 6-month consequences of COVID-19 in patients discharged from hospital: a cohort study. *Lancet* 2021;**397**:220–32. doi:10.1016/S0140-6736(20)32656-8

- 1
2
3 8 Hodgson CL, Udy AA, Bailey M, *et al.* The impact of disability in survivors of
4 critical illness. *Intensive Care Med* 2017;**43**:992–1001. doi:10.1007/s00134-
5 017-4830-0
6
7
8
9
10 9 Hatch R, Young D, Barber V, *et al.* Anxiety, Depression and Post Traumatic
11 Stress Disorder after critical illness: a UK-wide prospective cohort study. *Crit*
12 *Care* 2018;**22**:310. doi:10.1186/s13054-018-2223-6
13
14
15
16
17 10 Pun BT, Badenes R, Heras La Calle G, *et al.* Prevalence and risk factors for
18 delirium in critically ill patients with COVID-19 (COVID-D): a multicentre
19 cohort study. *Lancet Respir Med* 2021;**9**:239–50. doi:10.1016/S2213-
20 2600(20)30552-X
21
22
23
24
25
26 11 Pearlin LI, Mullan JT, Semple SJ, *et al.* Caregiving and the Stress Process:
27 An Overview of Concepts and Their Measures. *Gerontologist* 1990;**30**:583–
28 94. doi:10.1093/geront/30.5.583
29
30
31
32
33 12 Braithwaite J. Changing how we think about healthcare improvement. *BMJ*
34 2018;:k2014. doi:10.1136/bmj.k2014
35
36
37
38 13 De Jonghe B, Sharshar T, Lefaucheur J-P, *et al.* Paresis acquired in the
39 intensive care unit: a prospective multicenter study. *JAMA* 2002;**288**:2859–
40 67. doi:10.1001/jama.288.22.2859
41
42
43
44
45 14 Organ System Support. NHS Digit.
46 2020.https://datadictionary.nhs.uk/attributes/organ_system_supported.html
47 (accessed 1 Aug 2020).
48
49
50
51 15 Needham DM, Sepulveda KA, Dinglas VD, *et al.* Core Outcome Measures
52 for Clinical Research in Acute Respiratory Failure Survivors: An International
53 Modified Delphi Consensus Study. *Am J Respir Crit Care Med* 2017;:1–42.
54
55
56
57
58
59

- 1
2
3 doi:10.1164/rccm.201702-0372OC
4
5
6 16 Turnbull AE, Sepulveda KA, Dinglas VD, *et al.* Core Domains for Clinical
7
8 Research in Acute Respiratory Failure Survivors. *Crit Care Med*
9
10 2017;**45**:1001–10. doi:10.1097/CCM.0000000000002435
11
12 17 World Health Organization. The International Classification of Functioning,
13
14 Disability and Health (ICF). Geneva, Switzerland: World Health Organization;
15
16 2001.
17
18 18 Organización Mundial de la Salud (OMS). *Medición de la Salud y la*
19
20 *Discapacidad: manual para el cuestionario de evaluación de la discapacidad*
21
22 *de la OMS: WHODAS 2.0.* 2015.
23
24
25 19 Rockwood K, Theou O. Using the Clinical Frailty Scale in Allocating Scarce
26
27 Health Care Resources. *Can Geriatr J* 2020;**23**:210–5.
28
29 doi:10.5770/cgj.23.463
30
31
32 20 Nakajima H, Nishikimi M, Shimizu M, *et al.* Clinical Frailty Scale Score
33
34 Before ICU Admission Is Associated With Mobility Disability in Septic
35
36 Patients Receiving Early Rehabilitation. *Crit Care Explor* 2019;**1**:e0066.
37
38 doi:10.1097/CCE.0000000000000066
39
40
41 21 Geriatric Medicine Research of the Department of Medicine at Dalhousie
42
43 University. [https://www.dal.ca/sites/gmr/our-tools/clinical-frailty-scale/cfs-](https://www.dal.ca/sites/gmr/our-tools/clinical-frailty-scale/cfs-guidance.html)
44
45 [guidance.html](https://www.dal.ca/sites/gmr/our-tools/clinical-frailty-scale/cfs-guidance.html) (accessed 1 Aug 2020).
46
47
48 22 Vanpee G, Hermans G, Segers J, *et al.* Assessment of limb muscle strength
49
50 in critically ill patients: a systematic review. *Crit Care Med* 2014;**42**:701–11.
51
52
53 23 Hermans G, Clerckx B, Vanhullebusch T, *et al.* Interobserver agreement of
54
55 medical research council sum-score and handgrip strength in the intensive
56
57
58
59
60

- 1
2
3 care unit. *Muscle Nerve* 2012;**45**:18–25. doi:10.1002/mus.22219
- 4
5 24 Huang M, Chan KS, Zanni JM, *et al*. Functional Status Score for the ICU: An
6
7 International Clinimetric Analysis of Validity, Responsiveness, and Minimal
8
9 Important Difference. *Crit Care Med* 2016;**44**:e1155–64.
10
11 doi:10.1097/CCM.0000000000001949
12
13
- 14 25 González-Seguel F, Leppe J, Hidalgo-Cabalín V, *et al*. Chilean version of the
15
16 Functional Status Score for the Intensive Care Unit: a translation and cross-
17
18 cultural adaptation. *Medwave* 2019;**19**:e7439–e7439.
19
20 doi:10.5867/medwave.2019.01.7439
21
22
- 23 26 Camus-Molina A, González-Seguel F, Castro-Ávila AC, *et al*. Construct
24
25 Validity of the Chilean-Spanish Version of the Functional Status Score for the
26
27 Intensive Care Unit: A Prospective Observational Study Using Actigraphy in
28
29 Mechanically Ventilated Patients. *Arch Phys Med Rehabil* 2020;**101**:1914–
30
31 21. doi:10.1016/j.apmr.2020.04.019
32
33
- 34 27 Stienen MN, Geisseler O, Velz J, *et al*. Influence of the Intensive Care Unit
35
36 Environment on the Reliability of the Montreal Cognitive Assessment. *Front*
37
38 *Neurol* 2019;**10**. doi:10.3389/fneur.2019.00734
39
40
- 41 28 Delgado C, Araneda A, Behrens MI. Validación del instrumento Montreal
42
43 Cognitive Assessment en español en adultos mayores de 60 años.
44
45 *Neurología* 2019;**34**:376–85. doi:10.1016/j.nrl.2017.01.013
46
47
- 48 29 Bello-Lepe S, Alonso-Sánchez MF, Ortega A, *et al*. Montreal Cognitive
49
50 Assessment as Screening Measure for Mild and Major Neurocognitive
51
52 Disorder in a Chilean Population. *Dement Geriatr Cogn Dis Extra* 2020;:105–
53
54 14. doi:10.1159/000506280
55
56
57
58
59

- 1
2
3 30 Jutte JE, Needham DM, Pfoh ER, *et al.* Psychometric evaluation of the
4 Hospital Anxiety and Depression Scale 3 months after acute lung injury. *J*
5 *Crit Care* 2015;**30**:793–8. doi:10.1016/j.jcrrc.2015.04.006
6
7
8
9
10 31 Villoria E, Lara L. Assessment of the Hospital Anxiety and Depression Scale
11 for cancer patients. *Rev Med Chil* 2018;**146**:300–7. doi:10.4067/s0034-
12 98872018000300300
13
14
15
16
17 32 Hosey MM, Bienvenu OJ, Dinglas VD, *et al.* The IES-R remains a core
18 outcome measure for PTSD in critical illness survivorship research. *Crit Care*
19 2019;**23**:362. doi:10.1186/s13054-019-2630-3
20
21
22
23
24 33 Caamaño LW, Fuentes DM, González LB, *et al.* Adaptación y validación de
25 la versión chilena de la escala de impacto de evento-revisada (EIE-R). *Rev*
26 *Med Chil* 2011;**139**:1163–8. doi:10.4067/S0034-98872011000900008
27
28
29
30
31 34 Oeyen SG, Vandijck DM, Benoit DD, *et al.* Quality of life after intensive care:
32 A systematic review of the literature. *Crit Care Med* 2010;**38**:2386–400.
33 doi:10.1097/CCM.0b013e3181f3dec5
34
35
36
37 35 EuroQol - a new facility for the measurement of health-related quality of life.
38 *Health Policy (New York)* 1990;**16**:199–208. doi:10.1016/0168-
39 8510(90)90421-9
40
41
42
43
44 36 Zarate V, Kind P, Valenzuela P, *et al.* Social Valuation of EQ-5D Health
45 States: The Chilean Case. *Value Heal* 2011;**14**:1135–41.
46
47
48
49
50
51 37 Norman BC, Jackson JC, Graves JA, *et al.* Employment Outcomes After
52 Critical Illness. *Crit Care Med* 2016;**44**:2003–9.
53
54
55
56
57
58
59
60

- 1
2
3 38 Kamdar BB, Suri R, Suchyta MR, *et al.* Return to work after critical illness: a
4 systematic review and meta-analysis. *Thorax* 2020;**75**:17–27.
5
6 doi:10.1136/thoraxjnl-2019-213803
7
8
9
10 39 Leppe J, Munizaga B, Margozzini P. Physical activity and sedentary behavior
11 according National Health Survey 2016-17. *Medwave* 2019;**19**:SP74.
12
13 doi:10.5867/medwave.2019.S1
14
15
16
17 40 Aguilar-Farias N, Leppe Zamora J. Is a single question of the Global Physical
18 Activity Questionnaire (GPAQ) valid for measuring sedentary behaviour in
19 the Chilean population? *J Sports Sci* 2016;:1–6.
20
21 doi:10.1080/02640414.2016.1229010
22
23
24
25
26 41 Kho ME, Molloy AJ, Clarke FJ, *et al.* TryCYCLE: A Prospective Study of the
27 Safety and Feasibility of Early In-Bed Cycling in Mechanically Ventilated
28 Patients. *PLoS One* 2016;**11**:e0167561. doi:10.1371/journal.pone.0167561
29
30
31
32
33 42 Nunna K, Al-Ani A, Nikooie R, *et al.* Participant Retention in Follow-Up
34 Studies of Acute Respiratory Failure Survivors. *Respir Care* 2020;**65**:1382–
35
36 91. doi:10.4187/respcare.07461
37
38
39
40 43 Mehrholz J, Mückel S, Oehmichen F, *et al.* First results about recovery of
41 walking function in patients with intensive care unit-acquired muscle
42 weakness from the General Weakness Syndrome Therapy (GymNAST)
43
44 cohort study. *BMJ Open* 2015;**5**:e008828. doi:10.1136/bmjopen-2015-
45
46 008828
47
48
49
50
51 44 Thomas S, Mehrholz J. Health-related quality of life, participation, and
52 physical and cognitive function of patients with intensive care unit-acquired
53
54 muscle weakness 1 year after rehabilitation in Germany: the GymNAST
55
56
57
58
59
60

1
2
3 cohort study. *BMJ Open* 2018;**8**:e020163. doi:10.1136/bmjopen-2017-
4
5 020163
6

7
8 45 Braun V, Clarke V. Using thematic analysis in psychology. *Qual Res Psychol*
9
10 2006;**3**:77–101. doi:10.1191/1478088706qp063oa
11

12 46 Haines KJ, Hibbert E, McPeake J, *et al*. Prediction Models for Physical,
13
14 Cognitive, and Mental Health Impairments After Critical Illness: A Systematic
15
16 Review and Critical Appraisal. *Crit Care Med* 2020;**48**:1871–80.
17
18 doi:10.1097/CCM.0000000000004659
19

20
21 47 Canadian Institutes of Health Research. Guide to Knowledge Translation
22
23 Planning at CIHR: Integrated and End-of-grant Approaches. 2012.[www.cihr-](http://www.cihr-irsc.gc.ca/e/45321.html)
24
25 [irsc.gc.ca/e/45321.html](http://www.cihr-irsc.gc.ca/e/45321.html)
26
27
28
29

30
31 **Collaborators:** The IMPACCT COVID-19 study group includes (organized
32
33 alphabetically): Ana Castro-Avila, Agustín Camus-Molina, Catalina Merino-Osorio,
34
35 Felipe González-Seguel and Jaime Leppe; and the following additional
36
37 collaborators: Camilo Cáceres Parra, Eduardo González Tapia, Felipe Muñoz-
38
39 Muñoz, Fernanda Baus Auil, Javiera Aguilera Scarpati, Joaquín Olave, Macarena
40
41 Leiva-Corvalán, Pilar Castro and Yerko Villagra Jofré.
42
43
44
45

46
47 **Contributors:** ACA, CMO, FGS, and ACM contributed to the conception. ACA,
48
49 CMO, and FGS drafted the first version of the protocol manuscript. ACA, CMO,
50
51 FGS, ACM, and JL contributed to the study design and writing of the protocol. All
52
53 authors reviewed the manuscript and gave final approval of the version to be
54
55 published.
56
57
58
59

1
2
3
4
5
6 **Acknowledgements:** We want to acknowledge the Universidad del Desarrollo for
7
8 funding this research and each participating site for allowing us to use part of their
9
10 infrastructure (organized alphabetically): *Clínica Alemana de Santiago, Clínica*
11
12 *BUPA, Clínica INDISA, Hospital del Salvador, Hospital Metropolitano, Hospital*
13
14 *Regional Dr. Leonardo Guzmán de Antofagasta, and Hospital San Pablo de*
15
16 *Coquimbo.*
17
18
19
20


21 **Funding:** IMPACCT COVID-19 study is funded by Universidad del Desarrollo
22
23 (Grant number 2020-78) and sponsored by the Chilean National Agency for
24
25 Research and Development (ANID-0772). The funders had no role in the design,
26
27 collection, analysis of the study, and writing of this manuscript.
28
29
30
31

32
33 **Competing interest:** None declare.
34
35
36
37

38 **Figure caption:**
39
40
41

42 **Figure 1.** IMPACCT COVID-19 study flowchart.
43
44

45 COVID-19, coronavirus disease 2019; ICU, intensive care unit.
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60



Supplementary file

Topic guide for family members' interviews.

We are conducting these interviews to understand the experience of family members of patients who were admitted to intensive care during the pandemic.

ICU stay

Could you explain the circumstances that led to your family member being admitted to ICU? Who explained to you what was happening?

How were you informed of changes to the condition of your family member? Could you visit your family member during the ICU stay?

How was your experience? Did you have someone that you could share with how you were feeling? How did you manage to keep doing the day-to-day work considering what was going on?

If you had queries about your family member's condition, who could you talk to? How easy was it to talk to this person? Is there something in the way things were communicated that could have been done better?

How was your experience once you were transferred to the hospital ward? Did you feel that all your queries were solved before leaving? Did you feel that you were prepared to leave the ICU?

Return to home

Could you, please, tell me how was your experience when you first arrived back at your home?

Guides:

Can kind of things were difficult to do for your family member?

What kind of training/ support did you receive? How was this received?

What kind of information or support did you feel you needed when you first came back home?

How and when should this information or support have been given?

Topic guide for healthcare professionals' interviews

We are conducting these interviews to explore the challenges you faced while working in the ICU during the pandemic.

Preparation before the pandemic

1. What did your unit do to be prepared for the pandemic?

Guides:

What did you do to increase bed capacity? When were you informed about these changes?

Were there any changes to the shift rota to decrease the risk of infection? Did you buy new equipment? Did you receive training to learn how to use them? What was the procedure to access a COVID-19 test? How did you find out about this procedure?

Physical, emotional and intellectual challenges

COVID-19 was first identified in December 2019; therefore, the knowledge about diagnosis and treatment was scarce at the beginning.

2. Before the first arrived at your unit, what did you know about the symptoms? What lines of treatment did you think were the most effective? How did this perception change as you treated more patients?
3. Did you change the criteria to decide when to intubate or use non-invasive ventilation?
4. At the beginning of the pandemic around 50% of patients who were intubated died, how was your experience? Was it similar? If it was not, what do you think you did differently?
5. How did your team face this increase in workload for an extended period?
6. What kind of routines did you implement to deal better with stress and fatigue?
7. The pandemic can be seen as an extremely emotionally draining situation for those working in ICU, how was your experience emotionally? How this changed or affected your personal relationships?
8. Now with the benefit of hindsight, is there something regarding the treatment of these patients that you would have done differently? And regarding the self-care strategies, would you have done something differently?
9. Before we end this interview, I would like to ask you to think about a recommendation for health secretary. What would that be? What would you recommend to the health secretary to do differently?

STROBE Statement—checklist of items that should be included in reports of observational studies

	Item No.	Recommendation	Page No.
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the abstract	1
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	3
Introduction			
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	4
Objectives	3	State specific objectives, including any prespecified hypotheses	6
Methods			
Study design	4	Present key elements of study design early in the paper	7
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up and data collection	7-10
Participants	6	(a) <i>Cohort study</i> —Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up <i>Case-control study</i> —Give the eligibility criteria, and the sources and methods of case ascertainment and control selection. Give the rationale for the choice of cases and controls <i>Cross-sectional study</i> —Give the eligibility criteria, and the sources and methods of selection of participants	7 and Table 1
		(b) <i>Cohort study</i> —For matched studies, give matching criteria and number of exposed and unexposed <i>Case-control study</i> —For matched studies, give matching criteria and the number of controls per case	18-20
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	10-18
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	10-15 and Table 2
Bias	9	Describe any efforts to address potential sources of bias	20
Study size	10	Explain how the study size was arrived at	17-19 and Table 3

Continued on next page

Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	19
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding	19-21
		(b) Describe any methods used to examine subgroups and interactions	n/a
		(c) Explain how missing data were addressed	20
		(d) <i>Cohort study</i> —If applicable, explain how loss to follow-up was addressed <i>Case-control study</i> —If applicable, explain how matching of cases and controls was addressed <i>Cross-sectional study</i> —If applicable, describe analytical methods taking account of sampling strategy	20
		(e) Describe any sensitivity analyses	
Results			
Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	n/a
		(b) Give reasons for non-participation at each stage	n/a
		(c) Consider use of a flow diagram	Figure 1 (without results)
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders	n/a
		(b) Indicate number of participants with missing data for each variable of interest	n/a
		(c) <i>Cohort study</i> —Summarise follow-up time (eg, average and total amount)	n/a
Outcome data	15*	<i>Cohort study</i> —Report numbers of outcome events or summary measures over time	n/a
		<i>Case-control study</i> —Report numbers in each exposure category, or summary measures of exposure	n/a
		<i>Cross-sectional study</i> —Report numbers of outcome events or summary measures	n/a
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included	n/a
		(b) Report category boundaries when continuous variables were categorized	n/a
		(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	n/a

Continued on next page

Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	n/a
Discussion			
Key results	18	Summarise key results with reference to study objectives	n/a
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	22-23
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	n/a
Generalisability	21	Discuss the generalisability (external validity) of the study results	22
Other information			
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	32

*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at www.strobe-statement.org.